Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
Monica Iorfida1, Manuelita Mazza1, Elisabetta Munzone1
1Division of Medical Senology, European Institute of Oncology, IRCCS, Milano 20141, Italy.
Abstract:
The development of CDK 4/6 inhibitors has dramatically changed the therapeutic management of hormone receptor-positive (HR+) and HER2 negative metastatic breast cancer (MBC). In combination with fulvestrant, palbociclib, ribociclib and abemaciclib have each been approved for HR+/HER2- MBC following the results of randomized Phase III studies (PALOMA-3, MONALEESA-3, MONARCH-2) and shown a significant advantage in PFS. Data from clinical trials support the combination with aromatase inhibitors in the first line setting and with fulvestrant in the second line. Each agent is well tolerated, and most of the toxicities observed with this class of drugs are generally easily manageable and free from particular complications. The latest evidence from MONARCH-2 and MONALEESA-3 trials shows benefits in terms of overall survival (OS), suggesting an option of using fulvestrant in combination with CDK 4/6 inhibitors in the first line setting. Additional research is needed to determine optimal treatment sequencing, understand the mechanisms of resistance, and develop novel therapeutic strategies to overcome clinical resistance and further improve the outcomes of patients with HR+/HER- MBC. Key questions in the field include the further impact on progression-free survival, overall survival, and the role of continuing CDK 4/6 blockade beyond progression. The purpose of this review is to describe the clinical relevance of fulvestrant in combination with CDK 4/6 inhibitors in HR+/HER2- MBC patients, as well as to discuss the current controversies and evolving research areas.
Insights
Fulvestrant combined with CDK 4/6 inhibitors improves progression-free survival and overall survival in hormone receptor-positive metastatic breast cancer. Further research is needed to optimize treatment and overcome resistance.
Area of Science:
- Oncology
- Pharmacology
Background:
- Cyclin-dependent kinase (CDK) 4/6 inhibitors have transformed treatment for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC).
- Combinations of CDK 4/6 inhibitors (palbociclib, ribociclib, abemaciclib) with fulvestrant demonstrate significant progression-free survival (PFS) benefits in Phase III trials.
Purpose of the Study:
- To review the clinical significance of fulvestrant plus CDK 4/6 inhibitors in HR+/HER2- MBC.
- To discuss current controversies and emerging research in this therapeutic area.
Main Methods:
- Review of randomized Phase III clinical trials (PALOMA-3, MONALEESA-3, MONARCH-2).
- Analysis of data supporting first-line use with aromatase inhibitors and second-line use with fulvestrant.
- Evaluation of recent evidence on overall survival (OS) benefits.
Main Results:
- CDK 4/6 inhibitors plus fulvestrant show significant PFS advantage in HR+/HER2- MBC.
- These combinations are generally well-tolerated with manageable toxicities.
- Recent data suggest OS benefits, supporting first-line use of fulvestrant with CDK 4/6 inhibitors.
Conclusions:
- Fulvestrant in combination with CDK 4/6 inhibitors is a key treatment for HR+/HER2- MBC.
- Optimal sequencing, resistance mechanisms, and overcoming resistance require further investigation.
- Continued research aims to improve outcomes and address resistance to CDK 4/6 blockade.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
02:34Inhibition of Cdk Activity
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...